Biotech Company will Try to Revive Clinically Dead Patients

To this day, when a person is characterized “clinically dead”, there is not too much doctors can do to help. It is a condition during which the human body loses its ability to keep the blood circulating and also can not complete the procedure of breathing. Both of the above actions are performed with the help of medical equipment. As soon as the equipment stops providing assistance, the patient is declared dead. But, this may soon change.

Bioquark, an American biotechnology corporation based in Philadelphia, Pennsylvania, was recently given the “green light” to start trying to bring clinically dead people back to life. The request was approved by two separate review boards that belong to the National Institute of Health in both the United States and India.

This is something that has never been tried in the past. The first group will consist of 20 clinically dead patients who, after their closest relatives give their consent, will participate in this endeavor. It will last about six weeks and the entire procedure will take place in Anupam Hospital located in the city of Rudrapur of India.Clinic-Death

The research team, after an extensive phase of studying and reaching conclusions picked four different methods that will be used at the same time in order to maximize the probability of success. These methods are the following:

1) Stem cell injections directly into the brain that will be scheduled to take place two times per week.

2) Stimulating the nerves by targeting the upper limb’s median nerve with electric impulses. This is a non-invasive treatment, meaning that it does not require surgery or any other way of cutting through the patient’s skin.

3) Another non-invasive technique called transcranial laser therapy. It has already been tested on patients suffering from Parkinson’s disease, migraines, and a stroke. Scientists use light to bypass the skull, target specific areas and restart the healing abilities of the human body.

4) Injections of protein chains called peptides in the patient’s spinal cord every day.

Even though the whole trial sounds promising, especially when we take the number of different approaches, but we have to keep in mind that this is an unprecedented effort. It is more than certain that many new questions will emerge, perhaps more than the ones we will be able to answer, but the scientific method has proven to us in an enormous number of cases that even the smaller steps will eventually lead to an enormous breakthrough. Hopefully, clinical death will soon be just another reversible medical condition.